Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.7 |
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.7 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |